Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amosartan Plus
- Development stage
- Phase 4
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amosartan Plus (HCP1401) is a fixed-dose combination therapy developed by Hanmi Pharmaceutical for the treatment of hypertension. It integrates three distinct antihypertensive agents: amlodipine, a dihydropyridine calcium channel blocker (CCB); losartan, an angiotensin II receptor blocker (ARB); and chlorthalidone, a thiazide-like diuretic. This triple-combination approach addresses hypertension through multiple physiological pathways, including peripheral vasodilation, inhibition of the renin-angiotensin-aldosterone system (RAAS), and reduction of extracellular fluid volume via inhibition of renal sodium reabsorption. Amosartan Plus is specifically indicated for patients with stage 2 hypertension or those whose blood pressure is not sufficiently controlled by dual-combination therapies, offering a simplified dosing regimen to improve patient adherence and enhance cardiovascular risk management.
- Brand names
- Amosartan Plus
- Other names
- amlodipine + losartan + chlorthalidone
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on Amosartan Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amosartan Plus.